NGNE — Neurogene Inc.

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 107
• Website: https://www.neurogene.com

Latest SEC filings for NGNE

• SCHEDULE 13G — 2026-10-07
• SCHEDULE 13G — 2026-10-06
• SCHEDULE 13G — 2026-08-14
• 8-K — 2026-07-02
• 424B5 — 2026-07-02
• 424B5 — 2026-06-30
• 424B5 — 2026-06-30
• 8-K — 2026-06-29
• 8-K — 2026-06-08
• 8-K — 2026-06-04

Latest NGNE news

• 2026-10-13 — Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? (Zacks Investment Research)
• 2026-10-08 — Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy (seekingalpha_market)
• 2026-10-05 — Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (businesswire.com)

Abrir análisis completo

Educational tool only — not investment advice.